Aurobindo Pharma Clears US FDA Audit at Unit-V with Minor 3 Observations

The US FDA conducted a routine inspection at Apitoria Pharma's Unit-V facility, focusing on manufacturing compliance for generics. Form 483 observations are standard findings noted at inspection close, typically procedural in nature for pharma firms. Aurobindo will submit corrective actions promptly.

Key Highlights

Clean Closure: Inspection completed successfully with only 3 observations issued.

Procedural Nature: All points relate to documentation/processes, not core quality lapses.

Facility Scope: Covers Unit-V operations under strict cGMP standards.

Response Plan: Comprehensive reply to FDA within prescribed deadlines.

Business Continuity: No expected impact on production or US market supplies.

Source: Aurobindo Pharma BSE filing, US FDA inspection disclosure.